Atlantic Biologicals Introduces New UTI Test
| The Statens Serum Institut (SSI), Copenhagen, Denmark and Atlantic Biologicals Corp., Miami, FL US, have formed a partnership to introduce a new diagnostic product to North America. |
FlexicultTM, designed for testing for urinary tract infection (UTI), has been in use in Denmark and is now seeking regulatory approval for commercialization in the United States.
Niels Frimodt-Møller, MD, Scientific Officer Statens Serum Institut, indicated that Flexicult had received a strongly positive reception in local markets and that market research also supports an equally good response in the US.
Karen L. Moody, President Atlantic Biologicals, has stated, 'FlexicultTM is a truly innovative product for the detection and diagnosis of UTI, incorporating the technology of the established gold standard of testing and an easy, reliable and highly accessible analytical format.'
UTI has been identified as a significant public health problem afflicting more than half of all women in their lifetime and requiring a physician office visit and treatment with antibiotic. Overuse of antibiotics is seen as a challenge, and the family physician is directed to follow a principle of using the drug with the narrowest spectrum and least toxicity. Drug resistance in this type of infection is frequently noted. The use of FlexicultTM overseas has been seen to address a need for rapid determination of suspect pathogen and selection of relevant antibiotics.
NOTE: This item is from our 'historic' database and may contain information which is not up to date.
Source : Atlantic Biologicals [USA] View archived contact details
Is a subsidiary/distributor for
Statens Serum Institut, Denmark
Posted on February 6, 2008